Deep Brain Stimulation News and Research

RSS

Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms—most commonly the debilitating symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. The procedure is also used to treat essential tremor, a common neurological movement disorder. At present, the procedure is used only for patients whose symptoms cannot be adequately controlled with medications.

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.

19 Oct 2012

Extradural brain stimulation safe and effective for patients with Parkinson's

Electrical stimulation using extradural electrodes—placed underneath the skull but not implanted in the brain—is a safe approach with meaningful benefits for patients with Parkinson's disease, reports the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Oct 2012

Study demonstrates how new scientific knowledge drives novel treatments for spinal cord injuries

Research released today demonstrates how new scientific knowledge is driving innovative treatments for spinal cord injuries. Spinal cord damage is debilitating and life-altering, limiting or preventing movement and feeling for millions worldwide, and leading to chronic health conditions and pain.

16 Oct 2012

EHRs enhance quality of patient care in community-based settings

A new study by Weill Cornell Medical College researchers, published in the Journal of General Internal Medicine, provides compelling evidence that electronic health records (EHRs) enhance the quality of patient care in a community-based setting with multiple payers, which is representative of how medicine is generally practiced across the United States.

10 Oct 2012

Key tips on how to sleep better, have more sex and stress less

Making the time to take care of your body and fulfill your needs becomes increasingly more difficult with the pressures and stresses of a demanding schedule, fast-paced job and the increasing number of distractions around us.

4 Oct 2012

Study examines newly proposed DSM-5 criteria for autism spectrum disorder

Parents should not worry that proposed changes to the medical criteria redefining a diagnosis of autism will leave their children excluded and deemed ineligible for psychiatric and medical care, says a team of researchers led by psychologists at Weill Cornell Medical College.

3 Oct 2012

Fear hard to extinguish from the teenage brain

A new study by Weill Cornell Medical College researchers shows that adolescents' reactions to threat remain high even when the danger is no longer present. According to researchers, once a teenager's brain is triggered by a threat, the ability to suppress an emotional response to the threat is diminished which may explain the peak in anxiety and stress-related disorders during this developmental period.

28 Sep 2012

Boston Scientific receives CE MARK approval for Vercise DBS to treat Parkinson's

Boston Scientific Corporation received CE Mark approval for use of its Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease.

28 Sep 2012

NeuroSigma to launch Monarch eTNS system at 10th European Congress on Epileptology

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.

25 Sep 2012

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.

21 Sep 2012

Power of taxane-based chemotherapy drugs may be potentially underestimated

The power of taxane-based chemotherapy drugs are misunderstood and potentially underestimated, according to researchers at Weill Cornell Medical College in the September 15 issue of the journal Cancer Research.

18 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012

Weill Cornell to establish new child care center

Weill Cornell Medical College announced today that it will create a child care center for up to 60 children of its faculty, students and staff near its campus on the Upper East Side of Manhattan.

12 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Less than half of community-based substance abuse treatment programs in the United States currently make HIV testing available on-site or through referral. A new study led by researchers at Weill Cornell Medical College shows the cost-effectiveness of integrating on-site rapid HIV testing into drug treatment programs.

10 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Currently in the United States, there are over 1.5 million people living with Parkinson's and 50,000 new cases reported each year

30 Aug 2012

Deep-brain stimulation may stop uncontrollable shaking in patients with Parkinson's

Deep-brain stimulation (DBS) may stop uncontrollable shaking in patients with Parkinson's disease and essential tremor by imposing its own rhythm on the brain, according to two studies published recently by University of Alabama at Birmingham researchers in the journal Movement Disorders.

29 Aug 2012